| 1.74 0.12 (7.41%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.5 | 1-year : | 2.92 |
| Resists | First : | 2.14 | Second : | 2.5 |
| Pivot price | 1.85  |
|||
| Supports | First : | 1.55 | Second : | 1.29 |
| MAs | MA(5) : | 1.67 |
MA(20) : | 1.92 |
| MA(100) : | 2.35 |
MA(250) : | 2.97 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.5 |
D(3) : | 9.7 |
| RSI | RSI(14): 36.7 |
|||
| 52-week | High : | 8.27 | Low : | 1.55 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INM ] has closed above bottom band by 31.9%. Bollinger Bands are 4.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.74 - 1.75 | 1.75 - 1.76 |
| Low: | 1.57 - 1.58 | 1.58 - 1.59 |
| Close: | 1.73 - 1.74 | 1.74 - 1.75 |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Tue, 11 Nov 2025
InMed Pharmaceuticals: Innovating Cannabinoid-inspired Medicines, Backed by Real Revenue and Clear Path to Value - Investing News Network
Mon, 10 Nov 2025
Why pension funds invest in InMed Pharmaceuticals Inc. (MWG) stock - Jobs Report & Growth Focused Investment Plans - newser.com
Sat, 08 Nov 2025
InMed Pharmaceuticals Advances Alzheimer’s Program Amidst Strong Fiscal Start - MSN
Thu, 06 Nov 2025
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update - Newsfile
Thu, 06 Nov 2025
InMed (NASDAQ: INM) posts Q1 revenue of $1.12M as lead Alzheimer’s candidate advances - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 5.2 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -8.36 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.71 |
| Profit Margin | -165.2 % |
| Operating Margin | -141.2 % |
| Return on Assets (ttm) | -36.2 % |
| Return on Equity (ttm) | -72.1 % |
| Qtrly Rev. Growth | 1.7 % |
| Gross Profit (p.s.) | 0.71 |
| Sales Per Share | 2.07 |
| EBITDA (p.s.) | -3.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.21 |
| PEG Ratio | 0 |
| Price to Book value | 0.25 |
| Price to Sales | 0.83 |
| Price to Cash Flow | -0.54 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|